Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | October 04, 2021 | October 06, 2021 |
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | December 16, 2024 | December 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date October 04, 2021 · Filed October 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.33 · Expires 2031-10-04 | Direct | 32,500 |
Reported balance
After 2021-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-04 · Grant · Acquired 32,500 · Balance 32,500 F1: One-third (1/3) of the shares subject to the option will vest on October 4, 2022, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third (1/3) of the shares subject to the option will vest on October 4, 2022, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date.
Rani Therapeutics Holdings, Inc.
Report date December 16, 2024 · Filed December 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2033-05-24 | Direct | 0 |
Reported balance
After 2024-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-16 · Disposition to issuer · Disposed 101,276 · Balance 0 F1: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2033-05-24 | Direct | 101,276 |
Reported balance
After 2024-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-16 · Grant · Acquired 101,276 · Balance 101,276 F1: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2031-07-28 | Direct | 0 |
Reported balance
After 2024-12-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-16 · Disposition to issuer · Disposed 18,875 · Balance 0 F3: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options. F2: The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.44 · Expires 2031-07-28 | Direct | 135,896 |
Reported balance
After 2024-12-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-16 · Grant · Acquired 18,875 · Balance 135,896 F3: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options. F2: The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options.
F2: The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years.
F3: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Turtle Beach Corp
Report date February 03, 2017 · Filed February 10, 2017
Section 16 reporting ended · disclosed 2017-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,433 |
Ending reported balance
After 2017-02-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-02-03 · Disposition to issuer · Disposed 43,103 · Balance 25,032 F1: As previously reported, these are restricted shares that were granted on April 4, 2016 and were scheduled to vest on April 4, 2017. Also as previously reported, on February 3, 2017, the reporting person resigned from the board of directors of the issuer. As a result, pursuant to the terms of the award agreement, the shares were forfeited with no compensation due to the reporting person. Row 2 · 2017-02-03 · Disposition to issuer · Disposed 1,599 · Balance 23,433 F2: As previously reported, these are restricted shares that were granted on January 30, 2014 and were scheduled to vest annually on January 30, 2018. Also as previously reported, on February 3, 2017, the reporting person resigned from the board of directors of the issuer. As a result, pursuant to the terms of the award agreement, the shares were forfeited with no compensation due to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: As previously reported, these are restricted shares that were granted on April 4, 2016 and were scheduled to vest on April 4, 2017. Also as previously reported, on February 3, 2017, the reporting person resigned from the board of directors of the issuer. As a result, pursuant to the terms of the award agreement, the shares were forfeited with no compensation due to the reporting person.
F2: As previously reported, these are restricted shares that were granted on January 30, 2014 and were scheduled to vest annually on January 30, 2018. Also as previously reported, on February 3, 2017, the reporting person resigned from the board of directors of the issuer. As a result, pursuant to the terms of the award agreement, the shares were forfeited with no compensation due to the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 18,875 | Not disclosed Strike: $9.44 | Not disclosed |
DisclosureSEC source: 0000950170-24-137316 · ownership.xml · derivative · entry 4 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,896 Underlying: Class A Common Stock · 18,875 shares Expires 2031-07-28 F3 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options. F2 · derivative.exercise_date: The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,875 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137316 · ownership.xml · derivative · entry 3 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 18,875 shares Expires 2031-07-28 F3 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options. F2 · derivative.exercise_date: The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-24-137316 · ownership.xml · derivative · entry 2 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137316 · ownership.xml · derivative · entry 1 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| May 29, 2024 Filed May 30, 2024 16:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066580 · ownership.xml · derivative · entry 1 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 18,875 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071470 · ownership.xml · derivative · entry 4 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,875 Underlying: Class A Common Stock · 18,875 shares Expires 2031-07-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on April 20, 2022; and 1/36th of the shares subject to the option vest monthly over the following two years. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,875 | Not disclosed Strike: $9.44 | Not disclosed |
DisclosureSEC source: 0000950170-23-071470 · ownership.xml · derivative · entry 3 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,021 Underlying: Class A Common Stock · 18,875 shares Expires 2031-07-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F3 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on April 20, 2022; and 1/36th of the shares subject to the option vest monthly over the following two years. F3 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071470 · ownership.xml · derivative · entry 2 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-23-071470 · ownership.xml · derivative · entry 1 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:06 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-23-033045 · doc4.xml · derivative · entry 1 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| May 25, 2022 Filed May 27, 2022 08:30 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 41,416 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0000899243-22-019855 · doc4.xml · derivative · entry 1 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,416 Underlying: Class A Common Stock · 41,416 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 16:11 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $20.33 | $0.00 |
DisclosureSEC source: 0001209191-21-059813 · doc4.xml · derivative · entry 1 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2031-10-04 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to the option will vest on October 4, 2022, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 03, 2017 Filed Feb 10, 2017 16:25 UTC | Turtle Beach Corp HEAR · Entity 6255 | Disposition to issuerCommon Stock | 1,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001493761-17-000006 · wf-form4_148676194492852.xml · nonDerivative · entry 2 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,433 F2 · shares: As previously reported, these are restricted shares that were granted on January 30, 2014 and were scheduled to vest annually on January 30, 2018. Also as previously reported, on February 3, 2017, the reporting person resigned from the board of directors of the issuer. As a result, pursuant to the terms of the award agreement, the shares were forfeited with no compensation due to the reporting person. F2 · price: As previously reported, these are restricted shares that were granted on January 30, 2014 and were scheduled to vest annually on January 30, 2018. Also as previously reported, on February 3, 2017, the reporting person resigned from the board of directors of the issuer. As a result, pursuant to the terms of the award agreement, the shares were forfeited with no compensation due to the reporting person. Read SEC document |
| February 03, 2017 Filed Feb 10, 2017 16:25 UTC | Turtle Beach Corp HEAR · Entity 6255 | Disposition to issuerCommon Stock | 43,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001493761-17-000006 · wf-form4_148676194492852.xml · nonDerivative · entry 1 DEBUONO LAUREEN · CIK 0001034447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,032 F1 · shares: As previously reported, these are restricted shares that were granted on April 4, 2016 and were scheduled to vest on April 4, 2017. Also as previously reported, on February 3, 2017, the reporting person resigned from the board of directors of the issuer. As a result, pursuant to the terms of the award agreement, the shares were forfeited with no compensation due to the reporting person. F1 · price: As previously reported, these are restricted shares that were granted on April 4, 2016 and were scheduled to vest on April 4, 2017. Also as previously reported, on February 3, 2017, the reporting person resigned from the board of directors of the issuer. As a result, pursuant to the terms of the award agreement, the shares were forfeited with no compensation due to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.